The FDA has established a CBER Safety Council within its Center for Biologics Evaluation and Research to strengthen oversight of vaccines, gene and cell therapies and blood products after they reach the market, the agency announced Nov. 19. The council took effect that day.
The council will report directly to the center’s director and be separate from the product offices that review and approve the therapies, according to the FDA’s announcement. It replaces CBER’s longtime Safety Working Group. The FDA said the change is meant to ensure that postmarket safety oversight is done by a dedicated, cross-functional team with clear accountability.
The council will review postmarket safety signals across all CBER-regulated products, conduct benefit-risk assessments and recommend regulatory actions, including safety-related market withdrawals, according to the FDA. Its work will cover emerging safety concerns, potential labeling changes, risk-management measures and safety-related postmarket studies, and it will coordinate with the CDC and NIH using surveillance systems including the Vaccine Adverse Event Reporting System and the FDA’s Sentinel program. The FDA said it will release more details on the council’s structure and membership later.
The FDA is already weighing safety questions on gene therapies. This month, the agency said it is investigating reports of tumors, including cases of vector DNA integration into the genome, in patients treated with Novartis’ Zolgensma for spinal muscular atrophy, and is evaluating whether regulatory action is appropriate. It also investigated a boy’s death after Sarepta’s Elevidys in 2025.